After serving as the interim leader for almost two years, William Farrar will become CEO of The Ohio State University Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (The James), pending approval by The Ohio State University Board of Trustees.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
